文献速递免疫规划慢病防控与筛查卫生政策与健康促进

美国重组带状疱疹疫苗与老年预防服务的利用及价值比较

Real-world utilization and potential clinical and economic value of recombinant zoster vaccine and select preventive services recommended for older adults in the United States.
PubMed 文献 · Vaccine · 2025-12-06

本文通过针对性文献综述,检索2012—2022年EMBASE、Medline和Emcare数据库,比较美国≥50岁人群重组带状疱疹疫苗(RZV)与流感、肺炎球菌、破伤风-白喉/破伤风-白喉-百日咳(Td/Tdap)、乙肝疫苗及结直肠癌(CRC)筛查的利用与价值。结果显示2020年≥50岁人群2剂RZV利用率10.8%,低于其他多数服务;RZV每质量调整生命年增量成本效果比为1407—91156美元,临床与经济价值相似或更优但利用更有限。

要点

  • 2020年≥50岁人群2剂RZV利用率10.8%,低于流感、肺炎球菌、Td/Tdap疫苗及CRC筛查。
  • RZV对比不接种的ICER为每QALY 1407—91156美元,经济价值与多数对照服务相当或更优。
  • RZV临床与经济价值不劣于其他老年推荐预防服务,但实际利用明显不足。

核心结论

  • RZV的临床与经济价值与美国≥50岁人群其他推荐预防服务相似或更优,但利用更有限。

研究设计与样本

  • 针对性文献综述,检索EMBASE、Medline和Emcare 2012—2022年文献,共8755篇,分析最相关72篇。

主要发现

  • 2020年≥50岁人群2剂RZV利用率为10.8%。
  • 乙肝疫苗2018年利用率19.1%,流感疫苗2020年54.2—75.2%,Td/Tdap 2019年按年龄56.5—69.8%,肺炎球菌疫苗2020年≥65岁67.5%,CRC筛查2020年74.2%。

关键数值与推荐

  • RZV对比不接种带状疱疹疫苗(≥50岁)ICER为每QALY 1407—91156美元。
  • 流感疫苗对比不接种(≥65岁)ICER为8833—15001美元,Tdap对比Td(≥65岁)为17150—336108美元。
  • 乙肝疫苗对比不接种(≥50岁)ICER为371606—541461美元,肺炎球菌疫苗对比不接种(≥50岁)为15000—38000美元。
  • CRC筛查对比不筛查(≥50岁)为dominant至261000美元。

临床怎么用

  • 在老年预防服务规划中应关注RZV利用不足,结合经济价值证据提升接种覆盖。
  • 可将RZV与其他老年推荐预防服务的利用与成本效果进行横向比较以支持决策。

局限性

  • 为针对性文献综述而非原始研究,纳入72篇文献,利用率为文献汇总数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the real-world utilization and potential clinical and economic value of recombinant zoster vaccine (RZV) with five selected preventive services (influenza, pneumococcal, tetanus-diphtheria/tetanus-diphtheria-pertussis (Td/Tdap), and hepatitis B vaccination and colorectal cancer (CRC) screening) recommended for adults aged ≥50 years in the United States. METHODS: In this targeted literature review, EMBASE, Medline, and Emcare were searched for the most relevant publications during 2012-2022 that included utilization, clinical, and economic data for RZV and the five most relevant comparator preventive services. RESULTS: Of 8755 articles identified, the most relevant 72 were analyzed. Utilization among adults aged ≥50 years of 2-dose RZV (10.8 % in 2020) was lower than hepatitis B (19.1 % in 2018), influenza (54.2-75.2 % in 2020), (Td/Tdap) (56.5-69.8 % by age in 2019), and pneumococcal (67.5 % in 2020; ≥65 years) vaccines, and (CRC) screening (74.2 % in 2020). From economic modeling studies, estimated incremental cost-effectiveness ratios per quality-adjusted life-year were $1407-91,156 for RZV versus no herpes zoster vaccination (age ≥50 years), $8833-15,001 for influenza vaccines versus not (age ≥65 years), $17,150-336,108 for Tdap versus Td vaccines (i.e., the impact of adding protection against pertussis; age ≥65 years), $371,606-541,461 for hepatitis B vaccines versus not (age ≥50 years), $15,000-38,000 for pneumococcal vaccines versus not (age ≥50 years), and dominant to $261,000 for CRC screening versus not (age ≥50 years). CONCLUSIONS: The clinical and economic value of RZV appears to be similar or superior to the other analyzed preventive services recommended for people aged ≥50 years in the United States, but, despite this, utilization is more limited.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Gatwood J, Gomez-Espinosa E, Fusco N, et al. Real-world utilization and potential clinical and economic value of recombinant zoster vaccine and select preventive services recommended for older adults in the United States. Vaccine. 2025. PMID: 41353819. doi:10.1016/j.vaccine.2025.128015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。